secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-11-29T23:59:59+00:00
Accession:  0001104659-24-124097
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics announces 1-for-33 reverse stock split effective Dec 4, 2024
--------------------------------------------------------------------------------

- Reverse split ratio 1-for-33; effective 12:01 a.m. ET Dec 4, 2024; new CUSIP 89357L402.
- Post-split shares outstanding approx 696,233 (includes recent private placement shares).
- Split intended to regain compliance with Nasdaq minimum $1.00 bid price; no assurance of continued listing.
- Fractional shares rounded up; no change in authorized shares; symbol RNAZ remains.
- Vstock Transfer acting as exchange agent; stockholders need not take action.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924124097/0001104659-24-124097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924124097/tm2429720d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-124097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer